194P Clinical feasibility and oncological safety of targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: A prospective registry study

Abstract

Targeted axillary dissection (TAD) has been incorporated into current guidelines for patients presenting with initially node-positive breast cancer. However, previous studies carried on strict eligibility criteria for enrolling participants focusing in cN1 patients, and limited real-world data existed regarding the clinical feasibility and oncological safety of non-radioactive TAD for patients with initially node-positive breast cancer in clinical practice.